Articles tagged with Cancer Patients
Researchers found that skeletal muscles release interleukin-15, which helps to settle and activate T-cell precursors. This enables the immune system to fight chronic infections over long periods. Regular training may strengthen the immune system by increasing muscle mass.
A randomised clinical trial has shown that a chemotherapy combination of carboplatin and paclitaxel is more effective and better tolerated than previously recommended treatments for patients with advanced anal cancer. The study found that these patients lived seven months longer overall, experiencing less treatment side effects.
Researchers at Hollings Cancer Center found a strong association between elevated AGEs in the body and breast cancer risk, particularly among women consuming high-AGE diets. The study's results suggest that reducing AGE intake through healthier food choices and physical activity may help lower cancer risk.
A study combining 15 observational studies with 9,500 patients compared the risk of cancer recurrence and death associated with minimally invasive versus open radical hysterectomy for early-stage cervical cancer. The results showed no significant difference in overall survival between the two groups.
Ashion Analytics has been certified for the National Cancer Institute's MATCH program, offering a comprehensive genomic analysis of all possible cancer mutations in DNA and RNA. This allows for personalized treatment options and potentially life-changing outcomes.
A new AI-driven system called ModGraProDep has been developed to predict cancer survival and risk. This innovative tool uses probabilistic modeling and machine learning to provide personalized predictions for patients, enabling more effective treatment planning and improved patient outcomes.
A randomized trial of a hospice video educational tool found that patients who viewed the video were more likely to prefer hospice at end-of-life and had longer hospice use compared to those receiving verbal descriptions. Caregivers also reported greater knowledge and preferences for hospice care after viewing the video.
Recent studies by Hollings Cancer Center researcher Chanita Hughes-Halbert highlight the importance of effective chronic disease prevention and management for male minority prostate cancer patients and veterans. The research emphasizes the need for better training programs and social determinants-based approaches to address underlying ...
Researchers found that 40.2% of advanced cancer patients experienced functional impairment upon hospitalization, leading to longer stays and worse outcomes. Interventions addressing this issue could enhance care delivery and outcomes for highly symptomatic patients.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
Researchers found that blocking Bruton tyrosine kinase (BTK) protein with acalabrutinib reduced inflammation and improved breathing in patients with severe COVID-19. The study suggests a potential new treatment approach for hospitalized patients with low blood-oxygen levels and evidence of inflammation.
Researchers at Dartmouth Health have found that HPV vaccines effective in the US may not provide adequate protection for women in low- and middle-income countries due to differing prevalence of HPV strains. This has significant implications for cervical cancer prevention and treatment in these regions.
Researchers discovered that cancer cells generate a high number of errors when copying their DNA under treatment, fuelling resistance. Combining targeted therapy with DNA repair mechanism-targeting drugs may lead to more effective therapeutic strategies.
A new study led by Ohio State University researchers has identified a protein within immune cells called PCBP1 that helps shape optimal immune responses to cancer. Higher PCBP1 activity promotes cytotoxic T-cell functions, while lower levels trigger the expression of factors that suppress cancer immune responses.
A large international trial found that pembrolizumab more than doubled the progression-free survival time of patients with a specific subtype of advanced bowel cancer, compared to chemotherapy. The treatment also showed durable benefits, with 48.3% of patients experiencing no disease progression after two years.
Researchers found that patients in Huntsman at Home had reduced hospitalizations, emergency department visits, and cumulative charges compared to controls. The study demonstrated strong evidence for the care model, showing improved patient outcomes while improving value.
A Phase II clinical trial has demonstrated a 46.5% objective response rate to tepotinib in patients with advanced non-small cell lung cancer and the MET exon 14 skipping mutation. The study's findings provide a new treatment option for this elderly population, with a durable response lasting almost one year.
A phase III clinical trial has shown that immunotherapy drug 'avelumab' significantly improves survival in patients with the most common type of bladder cancer. Treatment with avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
A multinational consortium reports that people with cancer have a higher risk of dying from COVID-19, particularly those with active cancer and impaired performance status. The study found no association between cancer treatments and 30-day mortality, suggesting that these therapies can continue during the pandemic with caution.
Oncologists are calling for more time spent on education about palliative care and discussing 'bad news' with patients. Research shows cancer doctors have limited coaching in this area, which can impact patient preferences for treatment or palliative care.
Researchers identified WWP1 mutations as a genetic driver of PTEN hamartoma tumor syndrome-associated cancer. The study found that WWP1 variants lead to abnormal activation of the enzyme inhibiting PTEN function and contributing to cancer development, suggesting a new therapeutic target.
A new app calculates individualized mortality risk assessment for cancer patients receiving immediate versus delayed treatment. The OncCOVID app draws on global cancer and coronavirus data to create personalized assessments, providing doctors with a tool to balance treatment needs against COVID-19 risks.
Dana-Farber nurse-scientists have received major research grants to develop innovative smoking cessation programs and study the causes of chemotherapy-induced peripheral neuropathy. The projects aim to improve lung health and treatment outcomes for cancer patients.
The dose-adjusted (DA) EPOCH-R regimen was found to be highly effective and better tolerated than standard chemotherapy for adults with Burkitt lymphoma. The treatment was effective across age groups, including patients in their 70s and 80s, and regardless of HIV status.
Researchers have found that genetic mutations from birth can promote cancer metastasis, with a single gene variant ApoE4 associated with slower tumor growth and better immune response. This discovery may lead to personalized treatment approaches for patients based on their genetics.
A study found that breast cancer survivors underutilize recommended strategies for reducing fatigue, despite high prevalence and persistence. The analysis also revealed differences in utilization of physical activity and supportive care depending on the type of fatigue experienced.
A key cell signaling pathway drives cancer-associated muscle loss, and targeting this pathway with a drug like GKT137831 could prevent cachexia. The study found that restoring SIRT1 levels can prevent muscle degeneration and extend the life of mice with pancreatic cancer
During the COVID-19 pandemic, bladder cancer patients with low-risk tumors can be safely managed with active surveillance, while those with high-risk tumors should proceed with active treatment. For muscle-invasive bladder cancer, radical cystectomy with urinary diversion is recommended.
The University of South Australia has received a $2.7 million grant to further develop anti-bacterial technologies for medical devices, building on existing successes in diagnostics and prognostics. The project aims to create nanotechnology-inspired solutions to improve patient outcomes and reduce infections.
A Monash University study found that inhibiting cell death pathways in oocytes allows them to rapidly repair DNA damage, maintaining fertility. Double-strand breaks are the most harmful type of DNA damage, promoting genetic instability if not repaired correctly.
Researchers at Hollings Cancer Center have developed a novel flow cytometry technique to quantify protein production in T-cells. This study reveals that T cells with robust protein production are more effective at controlling tumor growth.
A new study by The Institute of Cancer Research reveals that delays in cancer surgery due to the Covid-19 pandemic could result in thousands of additional deaths. The modelling suggests that a three-month delay would lead to an additional 4,755 deaths and 92,214 years of life lost.
Researchers developed TransPRECISE to combine molecular data, drug profiling, and cancer cell lines to understand tumor behavior. The tool accurately predicted potential therapeutic efficiency of drugs and identified key targets.
A review of lung cancer treatments for patients with COVID-19 was published to assist oncologists in addressing the challenges presented by these patients. The guidelines balance risk of exposure and infection with effective care, taking into account existing comorbidities.
A new study estimates that approximately one in ten people in the US with symptoms caused by major vascular events, infections, or cancers will be misdiagnosed. The study found that these conditions are among the most frequently misdiagnosed, resulting in significant harm and disability.
A clinical trial led by Mount Sinai researchers showed that combining chemotherapy and immunotherapy can significantly delay the progression of metastatic bladder cancer. The trial also found that immunotherapy alone may be an option for patients with high PD-L1 protein expression in their tumors.
A recent NIH-funded project explores how the fear of cancer recurrence affects the well-being and relationships of breast cancer patients and their spouses. The research team, led by Jean-Philippe Laurenceau, will focus on three main health behaviors that can be influenced by recurrence fears.
Researchers developed prediction tools to identify patients at risk of delayed post-operative radiotherapy, which can improve survival rates. The nomograms consider individualized risk factors and stage 4 cancer as key variables associated with delays.
A recent study by MSK Kids researchers found that pediatric cancer patients do not have a higher risk of COVID-19 infection or morbidity. In fact, only 95% of children with cancer infected with COVID-19 had mild symptoms and did not require hospitalization.
Researchers with the ECOG-ACRIN Cancer Research Group presented new findings on breast cancer treatment trials, including TAILORx and NCI-MATCH. The studies found that women under 40 are at risk for early discontinuation of hormone therapy, and insurance status plays a key role in adherence to adjuvant hormone therapy.
A new study reveals that children with cancer in New York are disproportionately affected by COVID-19, with a higher risk of severe illness. The research highlights the importance of prioritizing vaccine administration and infection control measures to protect these vulnerable patients.
The trial found that reduced postoperative radiation therapy in intermediate-risk patients with HPV+ oropharynx squamous cell carcinoma is safe and effective, with very good oncologic outcomes. Patients at low risk had favorable two-year progression-free survival without postoperative therapy.
Primary care clinicians perceive their role in caring for cancer survivors, but approaches vary widely. Researchers recommend coordinating care between primary care and oncologists to address complex needs.
The Cancer IO project aims to drive creation of a Finnish IO ecosystem and national IO growth strategy, boosting business competitiveness and individualization of care. With 10 million euros funding, the project will support top-level research and development of cancer immunotherapy treatments.
A new saliva test has detected early throat cancer in a person with no symptoms, highlighting a potential breakthrough in cancer screening. The test identified HPV-DNA in the saliva of an infected individual, allowing for early removal of the affected tonsil through surgery.
A clinical trial found that olanzapine significantly improved patient quality of life by reducing nausea and vomiting scores. The study showed that patients who received olanzapine reported less vomiting, better appetite, and better well-being compared to those who received a placebo.
A recent analysis of published studies found that many cancer survivors lack awareness of financial toxicity and are unprepared for its impacts. Despite coping mechanisms, they still have unmet needs for managing financial toxicity.
Research reveals that small chromosomes have a higher rate of DNA double-strand breaks to ensure proper recombination and segregation. This 'boost' helps explain how small chromosomes punch above their weight, ensuring recombination on every chromosome.
A new study discovered that tumor markers for various cancers also predict heart failure severity and mortality in patients with heart failure. The study found strong correlations between cancer markers and known heart failure indicators, suggesting a relationship between cancer and cardiovascular disease.
A recent survey found that enrollment in supportive oncodermatology programs is associated with improved quality of life scores among cancer patients. The study, published in the Journal of Drugs in Dermatology, highlights the benefits of these interventions on patient dermatologic health and overall well-being.
Researchers analyzed ATAC-seq data from 404 cancer patients to correlate chromatin accessibility with tumor characteristics, age, sex, and survival rates. The study found that chromatin accessibility on the X chromosome is strongly dependent on patient sex, but not on age or tumor stage.
A study of over 12,000 patients found that those with abnormally small red blood cells had a higher risk of cancer. The research suggests that microcytosis could be an early indicator of various cancers.
A large study of cancer patients with COVID-19 reveals a dramatically high case-fatality rate of 28%, significantly higher than the overall US mortality rate. The study emphasizes the importance of preventing cancer patients from contracting COVID-19 and closely monitoring for dangerous symptoms.
Scientists at Huntsman Cancer Institute have discovered the protein LEM2 plays two vital roles during cell division: sealing damaged DNA and recruiting factors that disassemble fibers separating DNA sets. This process may be critical for understanding cancer development and progression.
A new form of local chemotherapy using a mitomycin-containing reverse thermal gel has been shown to be effective in treating low-grade upper tract urothelial cancer, allowing patients to keep their kidney. The treatment has a high complete response rate and is associated with manageable side effects.
The FDA has approved encorafenib in combination with cetuximab for patients with advanced BRAF-mutated colorectal cancer. This new treatment is the result of DNA-guided personalized cancer treatment research by the SU2C-Dutch Cancer Society team.
Researchers at MD Anderson Cancer Center and Ipsen Biopharmaceuticals have developed a novel drug, IPN60090, a glutaminase inhibitor for lung and ovarian cancers. The Phase I clinical trial shows promising results, particularly for patients with KEAP1/NRF2 mutations or low ASNS levels.
Prolgolimab, a Russian original PD-1 inhibitor, has been approved for the treatment of advanced melanoma. The drug demonstrated significant antitumor activity and manageable safety in a phase II study, with 42 out of 126 patients experiencing an objective response.
Research highlights continued support for immunotherapy approaches to pediatric ALL and lung cancer, as well as progress in Cancer Interception. The studies aim to identify genes that may be responsible for immune suppression or activation in Bronchial premalignant lesions.
A nanomedicine expert proposes a cancer care model for managing COVID-19, focusing on early detection, regular monitoring, and targeted treatment. This approach could improve patient outcomes by providing systematic management of the pandemic.